MAPT and Alzheimer disease: For example, tau cleavage by caspase-3 at D421 occurs early in disease development, following an alteration in tau conformation detected by the Alz50 antibody, and prior to the formation of the conformational Tau-66 epitope (tau residues 155–244 and 305–331) which is detected in late-stage AD (56).